Format

Send to

Choose Destination
Anticancer Res. 2016 Dec;36(12):6511-6513.

Long-term High-quality Survival with Single-agent Mifepristone Treatment Despite Advanced Cancer.

Author information

1
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology & Infertility, Cooper Medical School of Rowan University, Camden, NJ, U.S.A. laurie@ccivf.com.
2
Cooper Institute for Reproductive Hormonal Disorders, P.C., Mt. Laurel, NJ, U.S.A.

Abstract

CASE REPORT:

We show long-term high-quality survival following single-agent treatment with a progesterone receptor antagonist in two cases of advanced metastatic cancer. Because no biopsy was performed (patient refused) the exact type of lung cancer was not determined but the majority of oncologists who evaluated the patient thought that the rapid onset and syndrome of inappropriate anti-diuretic hormone was more consistent with small-cell lung cancer. The US Food and Drug Association granted a compassionate-use investigational new drug approval for use of single-agent 200 mg mifepristone orally/day to a moribund woman with never-treated metastatic lung cancer and a male with bilateral renal cell carcinoma who had undergone only a unilateral hemi-nephrectomy. Both had long-term high-quality survival (5 years for the patient with lung cancer with complete remission of all lung lesions, and 12 years for the male patient with kidney cancer). Neither patient had any side-effects from mifepristone therapy.

CONCLUSION:

These cases helped influence the US Food and Drug Association in granting an investigator-initiated investigational new drug study on advanced non-small cell lung cancer.

KEYWORDS:

Renal cell carcinoma; advanced metastatic cancer; case report; compassionate use; lung cancer; mifepristone; progesterone receptor antagonist

PMID:
27919975
DOI:
10.21873/anticanres.11251
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center